Source: Υπουργείο Υγείας (CY) Revision Year: 2014 Publisher: Medochemie Ltd, 1-10 Constantinopoleos Street, 3011 Limassol, Cyprus
A sufficient amount of liquid should be taken during treatment to maintain an adequate level of diuresis.
Clarantin contains carmoisine which may cause allergic reactions.
None known.
There is no information on potential interactions with other drugs or other forms of interaction.
There is inadequate evidence of the safety of naftidrofuryl oxalate in human pregnancy, although it has been in wide use for many years without apparent ill consequence. Animal studies having shown no hazard. If drug therapy is required during pregnancy, Clarantin could be used if there is no safer alternative.
There is no information available and Clarantin should not be used during lactation.
Clarantin has no influence on the ability to drive and use machines.
Naftidrofuryl oxalate is normally well tolerated in the dosage recommended:
Rare: Nausea, hepatitis, epigastric pain and rashes.
Very rare: Calcium oxalate kidney stones.
Reporting suspected adverse reactions is an important way to gather more information to continuously monitor the benefit/risk balance of the medicinal product. Any suspected adverse reactions should be reported to Pharmaceutical Services, Ministry of Health, CY-1475, www.moh.gov.cy/phs, Fax: +357 22608649.
No known incompatibilities.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
